Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Monday, January 30, 2017

Scientists describe lab technique with potential to change medicine and research

If any good at all our fucking failures of stroke associations would be contacting stroke researchers to see how this could be used to create various neurons to help recovery. But that will never occur since we have NO stroke leadership and NO stroke strategy.  You are on your own to solve your own stroke problems, your doctors are worthless.
https://www.mdlinx.com/pharma-news/top-medical-news/article/2017/01/30/7?
 
Georgetown University Medical Center News
Researchers who developed and tested a revolutionary laboratory technique that allows for the endless growth of normal and diseased cells in a laboratory are publicly sharing how the technique works.

The Georgetown University Medical Center (GUMC) researchers hope that by doing so, scientists around the world can realize the many of possibilities of “conditional reprogramming,” which includes living biobanks, personalized and regenerative medicine, and novel cancer research.

Published in the journal Nature Protocols, investigators demonstrate how conditional reprogramming (CR) works, and why it may be able to fill a number of clinical care and research voids.

CR is the only known system that can indefinitely grow healthy as well as cancer cells “as if they were just extracted from a patient, and expand them — a million new cells can be grown in a week — as long as needed,” says the co–lead author Xuefeng Liu, MD, associate professor of pathology and a director in the Center for Cell Reprogramming at Georgetown University Medical Center.

No genetic modification is needed to coax the cells to grow — all that is used are special “feeder” cells and a chemical inhibitor.

As one example, the researchers demonstrate they are able to use CR to produce new and healthy pancreatic beta islet cells that secrete insulin — suggesting a promising avenue for type I diabetes research.

“A true cure for this kind of diabetes could be achieved by replacing the lost beta cells with new functional insulin producing cells,” says Liu.

The researchers have also grown healthy and cancerous cells from airway tissues, retinas, prostates, breasts, and intestines, which replicate for extended periods with conditional reprogramming.

Since CR was developed and described by Liu, Richard Schlegel, MD, PhD, director of the Center for Cell Reprogramming, and their colleagues at Georgetown in 2011, scientists have been testing the ability of the cells to perform a number of advanced goals. The CR method has spread worldwide, for example, the National Cancer Institute cited the CR method in Precision Medicine Initiatives for oncology and drug discovery programs. Georgetown researchers have trained more than 100 scientists in the technique.

In the newly published protocol, the Georgetown researchers describe many other possibilities that CR offers: among them, living biobanks, personalized and regenerative medicine, and novel cancer research.

Additionally, biobanking normal cells from a patient allows the possibility of using those cells in the future to infuse healthy cells into a damaged organ. “We can grow cells, freeze them, thaw them,” Liu says. “Think about use of such cells for skin replacement, for organ patching, and cancer studies.”

CR cancer cells also could allow oncologists to test and select a therapy based on an expanded laboratory population of a patient’s individual cancer cells — a procedure already conducted at Georgetown and published in the New England Journal of Medicine. An independent research study at Massachusetts General Hospital Cancer Center, published in Science, demonstrated that the CR method identified a combination of therapies for resistant lung cancer patients.

Several institutes have used CR platform for discovery of anti–cancer drug or new targets.

It may also be possible to fix damaged cells, using gene editing techniques, and then grow new, repaired cells to fix a wide variety of diseases, Liu says. “It is not unimaginable that we could take a tiny nose biopsy from a person with cystic fibrosis, correct the defect that causes the disease, then regrow the healthy cells to infuse back into the lung. Because the cells were derived from the patient, they would not be rejected.”

No comments:

Post a Comment